BRAF and ganglioglioma: None of the gangliogliomas in this cohort showed genetic alterations in components of this pathway, except for one ganglioglioma that recurred after gross total resection and harbored a subclonal PTEN missense mutation (in addition to BRAF p.V600E mutation and CDKN2A homozygous deletion).